Emergent BioSolutions | EBS - 流动资产



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 479.2M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


流动资产 更改 日
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Akebia Therapeutics USD 243.48M 9.47M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amarin USD 626.02M 23.87M 2026-03
ANI Pharmaceuticals USD 747.08M 6.03M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Coherus Biosciences USD 206.71M 254.25M 2025-12
Emergent BioSolutions USD 679.5M 41.3M 2023-12
Exelixis USD 1.21B 234.65M 2026-03
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Heron Therapeutics USD 228.98M 9.08M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Ironwood Pharmaceuticals USD 332.29M 58.11M 2026-03
Lexicon Pharmaceuticals USD 186.03M 84.14M 2026-03
Lonza CHF 8B 3.41B 2025-12
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Myriad Genetics USD 312.8M 19.8M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Pacira USD 514.96M 33.01M 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Xoma USD 110.71M 5.78M 2025-09